ALKERMES | ALKS - Gross Profit On Sales



ALKERMES reported $257.77M in Gross Profit on Sales for its fiscal quarter ending in June of 2025.


Gross Profit On Sales Change Date
AbbVie USD 9.34B 1.36B Mar/2025
Acadia Pharmaceuticals USD 243.83M 19.91M Jun/2025
ALKERMES USD 257.77M 462K Jun/2025
Amgen USD 6.17B 624M Jun/2025
Biogen USD 2.04B 238.8M Jun/2025
BioMarin Pharmaceutical USD 670.47M 76.89M Jun/2025
Bristol-Myers Squibb USD 8.9B 714M Jun/2025
Eli Lilly USD 13.11B 2.61B Jun/2025
Gilead Sciences USD 5.58B 453M Jun/2025
Ionis Pharmaceuticals USD 448M 317.85M Jun/2025
J&J USD 14.6B 816M Mar/2025
Malin Corporation EUR 3.8M 2.6M Dec/2020
Merck USD 12.99B 224M Jun/2025
Neurocrine Biosciences USD 676.2M 112.8M Jun/2025
Otsuka Holdings JPY 429.15B 2.96B Jun/2025
Pfizer USD 10.88B 248M Jun/2025
Regeneron Pharmaceuticals USD 3.15B 581M Jun/2025
Vertex Pharmaceuticals USD 2.56B 150M Jun/2025